Pluristem plunges after COVID-19 treatment fails mid-stage trial

Pluri

27/12/2021 13:38

** U.S.-listed shares of Israeli regenerative medicine co,
Pluristem Therapeutics Inc  PSTI.O  down ~12% at $1.70
premarket; set to open at record low
    ** Interim data from mid-stage dose escalation studies of
co's investigational therapy, PLX-PAD cells, to treat acute
respiratory distress syndrome associated with COVID-19 failed to
achieve main goals  urn:newsml:reuters.com:*:nGNXQ7Z8M  
    ** Analysis based on 89 patients showed intramuscular
injections of PLX-PAD cells did not meet main goals of
statistically significant improvement in ventilator free days at
28 days - PSTI
    ** No differences in safety profile were observed between
PLX-PAD and placebo- co
    ** Up to Friday's close, stock had fallen 72.56% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))